Daiki Masukawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daiki Masukawa has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Yoshio Goshima
Department of Molecular Pharmacology and Neurobiology Yokohama City University Graduate School of Medicine Yokohama Japan
10 shared publications Masami Arai
Department of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
4 shared publicationsRei Tajika
Department of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
4 shared publications- Akira Yamashita
Department of Physiology, Kagoshima University Graduate School of Medical and Dental Science, Kagoshima, 890-8544, Japan
3 shared publications Kaori Kanai
Department of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine
3 shared publications- Shunpei Moriya
Department of Physiology, Kagoshima University Graduate School of Medical and Dental Science, Kagoshima, Japan
3 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 162 (3) , 197-205
Cholinergic neurons in the dorsal motor nucleus of the vagus contribute to vagally mediated cardiovascular responses through a putative pathway involving the nodose ganglion
- 27 August 2026
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 162 (3) , 197-205
Open AccessCholinergic neurons in the dorsal motor nucleus of the vagus contribute to vagally mediated cardiovascular responses through a putative pathway involving the nodose ganglion
- Open Access
- 7 April 2026
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 161 (2) , 32-35
Enhanced effect of the hallucinogen DOI in L-DOPA receptor Gpr143-deficient mice
- 7 April 2026
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 161 (2) , 32-35
Open AccessEnhanced effect of the hallucinogen DOI in L-DOPA receptor Gpr143-deficient mice
- Open Access
- 9 January 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (1) , e70080
Disruption of the l ‐ DOPA Receptor Gpr143/OA1 ‐Gene in Mice Creates a Unique Mixed Psychosis‐Like Phenotype
GPR143, originally identified as the gene product of ocular albinism 1 (OA1), a G protein‐coupled receptor (GPCR), can function as a receptor for l ‐3,4‐dihydroxyphenylalanine (DOPA), a precursor of dopamine (DA). To examine the physiological and pathophysiological roles of GPR143, we analyzed the behavior of Gpr143 gene‐deficient ( Gpr143 −/y ) mice. We performed comprehensive behavioral analyses including the prepulse inhibition test, sucrose preference test, light–dark exploration test, etc. and microarray analysis. Gpr143 −/y mice displayed a mixed psychosis‐like phenotype: impaired prepulse inhibition (a characteristic of schizophrenia) combined with reward system aberrations, depression, and heightened aggression (characteristic of mood disorders). By microarray analysis, we identified 17 downregulated and 20 upregulated genes in the forebrain of Gpr143 −/y mice, genes putatively involved in serotonergic and/or dopaminergic transmission. These findings suggest that GPR143 plays a role in mesolimbic and mesocortical functions underlying sensory gating, reward, social hierarchy, cognition, and emotional regulation. These data further suggest both a new animal model and a unique therapeutic focus for a heretofore difficult to study and treat mixed psychosis‐like condition.
- 9 January 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (1) , e70080
Open AccessDisruption of the l ‐ DOPA Receptor Gpr143/OA1 ‐Gene in Mice Creates a Unique Mixed Psychosis‐Like Phenotype
GPR143, originally identified as the gene product of ocular albinism 1 (OA1), a G protein‐coupled receptor (GPCR), can function as a receptor for l ‐3,4‐dihydroxyphenylalanine (DOPA), a precursor of dopamine (DA). To examine the physiological and pathophysiological roles of GPR143, we analyzed the behavior of Gpr143 gene‐deficient ( Gpr143 −/y ) mice. We performed comprehensive behavioral analyses including the prepulse inhibition test, sucrose preference test, light–dark exploration test, etc. and microarray analysis. Gpr143 −/y mice displayed a mixed psychosis‐like phenotype: impaired prepulse inhibition (a characteristic of schizophrenia) combined with reward system aberrations, depression, and heightened aggression (characteristic of mood disorders). By microarray analysis, we identified 17 downregulated and 20 upregulated genes in the forebrain of Gpr143 −/y mice, genes putatively involved in serotonergic and/or dopaminergic transmission. These findings suggest that GPR143 plays a role in mesolimbic and mesocortical functions underlying sensory gating, reward, social hierarchy, cognition, and emotional regulation. These data further suggest both a new animal model and a unique therapeutic focus for a heretofore difficult to study and treat mixed psychosis‐like condition.
- Open Access
- 29 July 2024
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 156 (2) , 77-81
Opposite regulation by L-DOPA receptor GPR143 of the long and short forms of the dopamine D2 receptors
- 29 July 2024
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 156 (2) , 77-81
Open AccessOpposite regulation by L-DOPA receptor GPR143 of the long and short forms of the dopamine D2 receptors
- Open Access
- 6 July 2024
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 156 (1) , 45-48
l-DOPA receptor GPR143 inhibits neurite outgrowth via L-type calcium channels in PC12 cells
- 6 July 2024
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 156 (1) , 45-48
Open Accessl-DOPA receptor GPR143 inhibits neurite outgrowth via L-type calcium channels in PC12 cells
- Open Access
- 29 January 2024
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 44 (11)
Enhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in Striatal Cholinergic Interneurons
Dopamine neurons play crucial roles in pleasure, reward, memory, learning, and fine motor skills and their dysfunction is associated with various neuropsychiatric diseases. Dopamine receptors are the main target of treatment for neurologic and psychiatric disorders. Antipsychotics that antagonize the dopamine D2 receptor (DRD2) are used to alleviate the symptoms of these disorders but may also sometimes cause disabling side effects such as parkinsonism (catalepsy in rodents). Here we show that GPR143, a G-protein-coupled receptor for L-3,4-dihydroxyphenylalanine (L-DOPA), expressed in striatal cholinergic interneurons enhances the DRD2-mediated side effects of haloperidol, an antipsychotic agent. Haloperidol-induced catalepsy was attenuated in maleGpr143 gene-deficient (Gpr143−/y) mice compared with wild-type (Wt) mice. Reducing the endogenous release of L-DOPA and preventing interactions between GPR143 and DRD2 suppressed the haloperidol-induced catalepsy in Wt mice but notGpr143−/ymice. The phenotypic defect inGpr143−/ymice was mimicked in cholinergic interneuron-specificGpr143−/y(Chat-cre;Gpr143flox/y) mice. Administration of haloperidol increased the phosphorylation of ribosomal protein S6 at Ser240/244in the dorsolateral striatum of Wt mice but notChat-cre;Gpr143flox/ymice. In Chinese hamster ovary cells stably expressing DRD2, co-expression of GPR143 increased cell surface expression level of DRD2, and L-DOPA application further enhanced the DRD2 surface expression. Shorter pauses in cholinergic interneuron firing activity were observed after intrastriatal stimulation in striatal slice preparations fromChat-cre;Gpr143flox/ymice compared with those from Wt mice. Together, these findings provide evidence that GPR143 regulates DRD2 function in cholinergic interneurons and may be involved in parkinsonism induced by antipsychotic drugs.
- 29 January 2024
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 44 (11)
Open AccessEnhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in Striatal Cholinergic Interneurons
Dopamine neurons play crucial roles in pleasure, reward, memory, learning, and fine motor skills and their dysfunction is associated with various neuropsychiatric diseases. Dopamine receptors are the main target of treatment for neurologic and psychiatric disorders. Antipsychotics that antagonize the dopamine D2 receptor (DRD2) are used to alleviate the symptoms of these disorders but may also sometimes cause disabling side effects such as parkinsonism (catalepsy in rodents). Here we show that GPR143, a G-protein-coupled receptor for L-3,4-dihydroxyphenylalanine (L-DOPA), expressed in striatal cholinergic interneurons enhances the DRD2-mediated side effects of haloperidol, an antipsychotic agent. Haloperidol-induced catalepsy was attenuated in maleGpr143 gene-deficient (Gpr143−/y) mice compared with wild-type (Wt) mice. Reducing the endogenous release of L-DOPA and preventing interactions between GPR143 and DRD2 suppressed the haloperidol-induced catalepsy in Wt mice but notGpr143−/ymice. The phenotypic defect inGpr143−/ymice was mimicked in cholinergic interneuron-specificGpr143−/y(Chat-cre;Gpr143flox/y) mice. Administration of haloperidol increased the phosphorylation of ribosomal protein S6 at Ser240/244in the dorsolateral striatum of Wt mice but notChat-cre;Gpr143flox/ymice. In Chinese hamster ovary cells stably expressing DRD2, co-expression of GPR143 increased cell surface expression level of DRD2, and L-DOPA application further enhanced the DRD2 surface expression. Shorter pauses in cholinergic interneuron firing activity were observed after intrastriatal stimulation in striatal slice preparations fromChat-cre;Gpr143flox/ymice compared with those from Wt mice. Together, these findings provide evidence that GPR143 regulates DRD2 function in cholinergic interneurons and may be involved in parkinsonism induced by antipsychotic drugs.
- Open Access
- 1 July 2023
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 46 (7) , 869-873
L-DOPA Receptor GPR143 Functionally Couples with Adrenergic α1B Receptor at the Second Transmembrane Interface
Adrenergic receptors (ADRs) are widely distributed in the peripheral and central nervous systems. We previously reported that L-3,4-dihydroxyphenylalanine (L-DOPA), the precursor of dopamine, sensitizes adrenergic α1 receptor (ADRA1) through a G protein-coupled receptor GPR143. Chimeric analysis, in which the transmembrane (TM) domains of GPR143 were replaced with those of GPR37, revealed that the second TM region was essential for the potentiation of phenylephrine-induced extracellular signal-regulated kinase (ERK) phosphorylation by GPR143. In HEK293T cells expressing ADRA1B, phenylephrine-induced ERK phosphorylation was augmented by the co-expression of GPR143, compared to the mock vector. Immunoprecipitation analysis revealed that a synthetic transactivator of the transcription peptide fused with TM2 of GPR143 (TAT-TM2) disrupts the interaction between GPR143 and ADRA1B. This TAT-TM2 peptide suppressed the augmentation of phenylephrine-induced ERK phosphorylation by GPR143 in HEK293T cells co-expressing ADRA1B and GPR143. These results indicate that the interaction between GPR143 and ADRA1B is required for the potentiation of ADRA1B-mediated signaling by GPR143. The TM2 region of GPR143 is a crucial dimeric interface for the functional coupling between ADRA1B and GPR143.
- 1 July 2023
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 46 (7) , 869-873
Open AccessL-DOPA Receptor GPR143 Functionally Couples with Adrenergic α1B Receptor at the Second Transmembrane Interface
Adrenergic receptors (ADRs) are widely distributed in the peripheral and central nervous systems. We previously reported that L-3,4-dihydroxyphenylalanine (L-DOPA), the precursor of dopamine, sensitizes adrenergic α1 receptor (ADRA1) through a G protein-coupled receptor GPR143. Chimeric analysis, in which the transmembrane (TM) domains of GPR143 were replaced with those of GPR37, revealed that the second TM region was essential for the potentiation of phenylephrine-induced extracellular signal-regulated kinase (ERK) phosphorylation by GPR143. In HEK293T cells expressing ADRA1B, phenylephrine-induced ERK phosphorylation was augmented by the co-expression of GPR143, compared to the mock vector. Immunoprecipitation analysis revealed that a synthetic transactivator of the transcription peptide fused with TM2 of GPR143 (TAT-TM2) disrupts the interaction between GPR143 and ADRA1B. This TAT-TM2 peptide suppressed the augmentation of phenylephrine-induced ERK phosphorylation by GPR143 in HEK293T cells co-expressing ADRA1B and GPR143. These results indicate that the interaction between GPR143 and ADRA1B is required for the potentiation of ADRA1B-mediated signaling by GPR143. The TM2 region of GPR143 is a crucial dimeric interface for the functional coupling between ADRA1B and GPR143.
- Open Access
- 28 April 2023
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 152 (3) , 178-181
Involvement of the L-DOPA receptor GPR143 in acute and chronic actions of methylphenidate
- 28 April 2023
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 152 (3) , 178-181
Open AccessInvolvement of the L-DOPA receptor GPR143 in acute and chronic actions of methylphenidate
- 9 March 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 165 (2) , 177-195
Coupling between GPR143 and dopamine D2 receptor is required for selective potentiation of dopamine D2 receptor function by L‐3,4‐dihydroxyphenylalanine in the dorsal striatum
Dopamine (DA) is involved in neurological and physiological functions such as motor control. L‐3,4‐dihydroxyphenylalanine (L‐DOPA), a precursor of DA, is conventionally believed to be an inert amino acid precursor of DA, and its major therapeutic effects in Parkinson's disease (PD) are mediated through its conversion to DA. On the contrary, accumulating evidence suggests that L‐DOPA itself is a neurotransmitter. We here show that L‐DOPA potentiates DA D2 receptor (DRD2) signaling through GPR143, the gene product of X‐linked ocular albinism 1, a G‐protein‐coupled receptor for L‐DOPA. In Gpr143‐gene‐deficient (Gpr143−/y) mice, quinpirole, a DRD2/DRD3 agonist, ‐induced hypolocomotion was attenuated compared to wild‐type (WT) mice. Administration of non‐effective dose of L‐DOPA methyl ester augmented the quinpirole‐induced hypolocomotion in WT mice but not in Gpr143−/y mice. In cells co‐expressing GPR143 and DRD2, L‐DOPA enhanced the interaction between GPR143 and DRD2 and augmented quinpirole‐induced decrease in cAMP levels. This augmentation by L‐DOPA was not observed in cells co‐expressing GPR143 and DRD1 or DRD3. Chimeric analysis in which the domain of GPR143 was replaced with GPR37 revealed that GPR143 interacted with DRD2 at the fifth transmembrane domain. Intracerebroventricular administration of a peptide that disrupted the interaction mitigated quinpirole‐induced behavioral changes in WT mice but not in Gpr143−/y mice. These findings provide evidence that coupling between GPR143 and DRD2 is required for selective DRD2 modulation by L‐DOPA in the dorsal striatum. image
- 9 March 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 165 (2) , 177-195
Coupling between GPR143 and dopamine D2 receptor is required for selective potentiation of dopamine D2 receptor function by L‐3,4‐dihydroxyphenylalanine in the dorsal striatum
Dopamine (DA) is involved in neurological and physiological functions such as motor control. L‐3,4‐dihydroxyphenylalanine (L‐DOPA), a precursor of DA, is conventionally believed to be an inert amino acid precursor of DA, and its major therapeutic effects in Parkinson's disease (PD) are mediated through its conversion to DA. On the contrary, accumulating evidence suggests that L‐DOPA itself is a neurotransmitter. We here show that L‐DOPA potentiates DA D2 receptor (DRD2) signaling through GPR143, the gene product of X‐linked ocular albinism 1, a G‐protein‐coupled receptor for L‐DOPA. In Gpr143‐gene‐deficient (Gpr143−/y) mice, quinpirole, a DRD2/DRD3 agonist, ‐induced hypolocomotion was attenuated compared to wild‐type (WT) mice. Administration of non‐effective dose of L‐DOPA methyl ester augmented the quinpirole‐induced hypolocomotion in WT mice but not in Gpr143−/y mice. In cells co‐expressing GPR143 and DRD2, L‐DOPA enhanced the interaction between GPR143 and DRD2 and augmented quinpirole‐induced decrease in cAMP levels. This augmentation by L‐DOPA was not observed in cells co‐expressing GPR143 and DRD1 or DRD3. Chimeric analysis in which the domain of GPR143 was replaced with GPR37 revealed that GPR143 interacted with DRD2 at the fifth transmembrane domain. Intracerebroventricular administration of a peptide that disrupted the interaction mitigated quinpirole‐induced behavioral changes in WT mice but not in Gpr143−/y mice. These findings provide evidence that coupling between GPR143 and DRD2 is required for selective DRD2 modulation by L‐DOPA in the dorsal striatum. image
- 19 January 2022
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 40 (2) , 215-226
L-DOPA-Induced Neurogenesis in the Hippocampus Is Mediated Through GPR143, a Distinct Mechanism of Dopamine
Neurogenesis occurs in the hippocampus throughout life and is implicated in various physiological brain functions such as memory encoding and mood regulation. L-3,4-dihydroxyphenylalanine (L-DOPA) has long been believed to be an inert precursor of dopamine. Here, we show that L-DOPA and its receptor, GPR143, the gene product of ocular albinism 1, regulate neurogenesis in the dentate gyrus (DG) in a dopamine-independent manner. L-DOPA at concentrations far lower than that of dopamine promoted proliferation of neural stem and progenitor cells in wild-type mice under the inhibition of its conversion to dopamine; this effect was abolished in GPR143 gene-deficient (Gpr143−/y) mice. Hippocampal neurogenesis decreased during development and adulthood, and exacerbated depression-like behavior was observed in adult Gpr143−/y mice. Replenishment of GPR143 in the DG attenuated the impaired neurogenesis and depression-like behavior. Our findings suggest that L-DOPA through GPR143 modulates hippocampal neurogenesis, thereby playing a role in mood regulation in the hippocampus.
- 19 January 2022
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 40 (2) , 215-226
L-DOPA-Induced Neurogenesis in the Hippocampus Is Mediated Through GPR143, a Distinct Mechanism of Dopamine
Neurogenesis occurs in the hippocampus throughout life and is implicated in various physiological brain functions such as memory encoding and mood regulation. L-3,4-dihydroxyphenylalanine (L-DOPA) has long been believed to be an inert precursor of dopamine. Here, we show that L-DOPA and its receptor, GPR143, the gene product of ocular albinism 1, regulate neurogenesis in the dentate gyrus (DG) in a dopamine-independent manner. L-DOPA at concentrations far lower than that of dopamine promoted proliferation of neural stem and progenitor cells in wild-type mice under the inhibition of its conversion to dopamine; this effect was abolished in GPR143 gene-deficient (Gpr143−/y) mice. Hippocampal neurogenesis decreased during development and adulthood, and exacerbated depression-like behavior was observed in adult Gpr143−/y mice. Replenishment of GPR143 in the DG attenuated the impaired neurogenesis and depression-like behavior. Our findings suggest that L-DOPA through GPR143 modulates hippocampal neurogenesis, thereby playing a role in mood regulation in the hippocampus.